<DOC>
	<DOCNO>NCT00923520</DOCNO>
	<brief_summary>Background : - Dimethane sulfonate ( DMS612 ) investigational drug administer human first time people advance tumor . More information maximum tolerate dose DMS612 help researcher identify whether drug suitable use treat certain kind cancer , particularly renal cell carcinoma . Objectives : - To determine maximum tolerate dose DMS612 ( high dose cause unacceptable side effect ) evaluate side effect . - To see DMS612 effect patient tumor blood test laboratory study . - To learn body process DMS612 . Eligibility : - Patients 18 year age old diagnose cancer respond well standard treatment . Design : - Pre-treatment evaluation visit determine eligibility : - Physical examination - Blood urine test - Chest X-ray ; electrocardiogram ; CAT scan chest , abdomen , pelvis , area body need - Other possible test , magnetic resonance imaging ( MRI ) positron emission tomography ( PET ) - Patients receive one dose DMS612 intravenous infusion week 3 week , follow 1 week without drug . Doses adjust base possible side effect cancer response . The disease evaluate three cycle drug . - Evaluations treatment period : - Physical examination review side effect . - Blood draw evaluate effectiveness drug , process body . - CAT scan end every two cycle ( every 8 week ) . - Other scan image procedure require study doctor .</brief_summary>
	<brief_title>A Phase 1 , Dose Escalation Study Safety , Tolerability , Pharmacokinetics Intravenous Dimethane Sulfonate ( DMS612 ) Advanced Malignancies</brief_title>
	<detailed_description>Background : - The dimethane sulfonates group agent identify active renal cell carcinoma NCI anticancer drug screen . - In vitro study show dimethane sulfonate property common alkylating agent , unlike conventional alkylators ( nitrogen mustard , BCNU , busulfan ) active renal cell carcinoma ( RCC ) . Objective : Primary : -To determine dose-limiting toxicity ( DLT ) , MTD recommend phase II dose ( RPTD ) dimethane sulfonate ( DMS612 , NSC 281612 ) administer intravenous ( IV ) bolus day 1 2 21-day cycle . Eligibility : - Patients must histologically confirm solid tumor malignancy lymphoma metastatic unresectable standard curative palliative measure exist longer effective . - Any prior chemotherapy therapy allow protocol . No 2 prior cytotoxic chemotherapy regimens allow . - Age great equal 18 year . Because dose adverse event data currently available use Dimethane sulfonate patient less 18 year age , child exclude study eligible future pediatric phase 1 single-agent trial . - ECOG performance status 0-2 ( Karnofsky great equal 60 % , ) . - Life expectancy 3 month great . - Patients must acceptable organ marrow function define : leukocyte great equal 3,000/mcL , absolute neutrophil count great equal 1,500/mm ( 3 ) , platelet great equal 100,000/ , mm ( 3 ) total bilirubin within normal institutional limit , AST ( SGOT ) /ALT ( SGPT ) , less equal 2.5 time institutional upper limit normal , creatinine within normal institutional limit creatinine clearance &gt; 50mL/min patient creatinine level institutional normal . Design : This Phase I study safety , pharmacokinetics , pharmacodynamics antitumor activity IV DMS612 , NSC 281612 , design open-label , dose-escalation study determine RPTD DMS612 , NSC 281612 base safety pharmacokinetics . With 02/09/2015 amendment change schedule evaluate day 1 2 dosing every 6 week follow schema use : Dose Level Dose NSC 281612 Escalation ( % ) - 1 3.5 mg/m2 Day 1 2 -33 4A 4.5 mg/m2 Day 1 2 -- - 5A 6 mg/m2 Day 1 2 33 6A 8 mg/m2 Day 1 2 67 7A 10.5 mg/m2 Day 1 2 33 7B 10.5 mg/m2 Day 1 2 q 6 week -- - 8A 14 mg/m2 Day 1 2 33 8B 14 mg/m2 Day 1 2 q 6 week --</detailed_description>
	<mesh_term>Lymphoma , Non-Hodgkin</mesh_term>
	<mesh_term>Carcinoma , Renal Cell</mesh_term>
	<mesh_term>Colonic Neoplasms</mesh_term>
	<criteria>INCLUSION CRITERIA : Patients must histologically confirm solid tumor malignancy lymphoma metastatic unresectable effective therapy exist longer effective . Any prior chemotherapy therapy allow protocol . No 2 prior cytotoxic chemotherapy regimen allow eligibility . Nonmyelotoxic therapy sunitinib sorafenib everolimus consider `` cytotoxic chemotherapy '' .Patients must great equal 4 week prior radiation cytotoxic chemotherapy , except great equal 6 week mitomycin C nitrosoureas ; great equal 2 week hormonal therapy ; great equal 4 week prior experimental therapy ; great equal 4 week monoclonal antibody therapy ( cetuximab , bevacizumab ) , great equal 2 week sorafenib , sunitinib temsirolimus great equal 8 week prior UCN01 treatment . Patients prostate cancer may continue ongoing LHRH agonist therapy . Patients bone metastasis hypercalcemia begin intravenous bisphosphonate treatment prior study entry may continue treatment . Age great equal 18 year . Because dose adverse event data currently available use dimethane sulfonate patient less 18 year age , child exclude study eligible future pediatric phase 1 singleagent trial . ECOG performance status 02 ( Karnofsky great equal 60 % , ) . Life expectancy 3 month great . Patients must acceptable organ marrow function define : leukocyte great equal 3,000/mm ( 3 ) absolute neutrophil count great equal 1,500/ mm ( 3 ) platelet great equal 100,000/ mm ( 3 ) total bilirubin within normal institutional limit AST ( SGOT ) /ALT ( SGPT ) less equal 2.5 time institutional upper limit normal creatinine within normal institutional limit OR 24 hour urine creatinine clearance great 50 mL/min/1.73 ( 2 ) patient creatinine level institutional normal ( may use creatinine clearance CockcroftGault Equation ) . The effect dimethane sulfonate develop human fetus unknown . For reason alkylating agent know teratogenic , woman childbearing potential men must agree use adequate contraception ( hormonal barrier method birth control ; abstinence ) prior study entry least 3 month study participation . Should woman become pregnant suspect pregnant participating study , inform treat physician immediately . Ability understand willingness sign write informed consent document . Willing comply study procedure followup . EXCLUSION CRITERIA : Patients recover ( CTC less equal grade I ) adverse event due prior treatment Patients may receive 2 prior cytotoxic regimen . Patients may receive investigational agent therapeutic anticancer intent . Patients history CNS metastasis , unless control achieve either radiation surgical resection least 3 month prior enrollment study . Patients radiation pelvis bone marrowbearing site consider case case basis may exclude bone marrow reserve consider adequate ( great 25 % bone marrow irradiate ) . Uncontrolled medical illness include , limited , ongoing active infection , chronic acute hepatitis , renal failure , symptomatic congestive heart failure , myocardial infarction within last 6 month , unstable angina pectoris , cardiac arrhythmia , psychiatric illness/social situation would limit compliance study requirement . Pregnant woman exclude study DMS612 likely toxicity similar alklyating agent potential teratogenic abortifacient effect . Because unknown potential risk adverse event nurse infant secondary treatment mother DMS612 , breastfeed discontinue mother treated DMS612 . HIVpositive patient combination antiretroviral therapy ineligible potential pharmacokinetic interaction DMS612 . In addition , patient increase risk lethal infection treat marrowsuppressive therapy . Appropriate study undertake patient receive combination antiretroviral therapy indicate . Patients eligible study take cytochrome P450inducing anticonvulsant . This apply patient brain metastasis take anticonvulsant another reason ( ie . Epilepsy ) . Patients diagnose alcoholism may treat disulfiram . Patients may receive agent think inhibit induce cytochrome p450 isoenzyme CYP3A4 .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>99 Years</maximum_age>
	<verification_date>October 21, 2016</verification_date>
	<keyword>Solid Tumors</keyword>
	<keyword>Phase I</keyword>
	<keyword>Lymphoma</keyword>
	<keyword>Dimethane Sulfonate ( DMS612 , NSC 281612 )</keyword>
	<keyword>Cancer</keyword>
	<keyword>Solid Tumor</keyword>
	<keyword>Renal Cell Cancer</keyword>
	<keyword>Kidney Cancer</keyword>
	<keyword>Breast Cancer</keyword>
	<keyword>Colon Cancer</keyword>
	<keyword>Lung Disease</keyword>
	<keyword>Non-Hodgkin Lymphoma</keyword>
	<keyword>NHL</keyword>
</DOC>